In Vivo Investigation Of Human PR3 Transgenic Mice: A Novel Animal Model To Understand The Role Of PR3 In Chronic Inflammation And Autoimmune Vasculitis
Funder
National Health and Medical Research Council
Funding Amount
$378,615.00
Summary
Granulomatosis with polyangiitis (GPA) is a form of vasculitis and is associated with antibodies directed against proteinase 3 (PR3). PR3 is expressed in neutrophils, monocytes and macrophages and has a number of well-characterized pro-inflammatory functions. The aim of this project is to understand the role of PR3 in inflammation and autoimmune vasculitis in vivo. This will be achieved using a transgenic mouse model expressing human PR3.
Exploring The Contribution Of Interferon-lambda To Autoimmune Disease
Funder
National Health and Medical Research Council
Funding Amount
$833,235.00
Summary
We have found that a novel protein, normally made in response to viral infections, is found in the blood of Lupus patients. This project will determine the cells that make this protein, what in Lupus blood makes these cells produce it and whether it plays a role in the severity of Lupus disease.
Pathogenesis Of A New Mouse Model Of Ankylosing Spondylitis
Funder
National Health and Medical Research Council
Funding Amount
$682,820.00
Summary
Ankylosing spondylitis and Crohn's disease are autoimmune inflammatory diseases which cause long-term pain and deformity of joints, spine and bowel. Using a new mouse model of both diseases, we will study cells and processes involved in the initiation of disease, in order to discover new targets for prevention and treatment. The work will have importance for design of new therapies for human inflammatory spine and bowel diseases.
The Role Of Susceptibility Genes And Microbiota In Inflammatory Diseases
Funder
National Health and Medical Research Council
Funding Amount
$303,924.00
Summary
Utilising my background in Immunology I will investigate whether specific genetic mutations can create a susceptibility for dysregulation of the flora and immune system within the gut, thus predisposing an individual to inflammatory bowel diseases (ulcerative colitis and Crohn's disease) as well as non-intestinal inflammatory conditions. These diseases are becoming an increasingly prevalent and serious health burden in Australia. We aim to use this knowledge in order to design specific treatment ....Utilising my background in Immunology I will investigate whether specific genetic mutations can create a susceptibility for dysregulation of the flora and immune system within the gut, thus predisposing an individual to inflammatory bowel diseases (ulcerative colitis and Crohn's disease) as well as non-intestinal inflammatory conditions. These diseases are becoming an increasingly prevalent and serious health burden in Australia. We aim to use this knowledge in order to design specific treatments for these diseases.Read moreRead less
I am the leading scientist studying a factor named BAFF and discovered its role in autoimmunity. BAFF inhibitors are effective in late stage clinical trials treating lupus patients. Our new work shows that BAFF has other fascinating roles, in particular the ability to control effects from some microbes capable of activating autoimmune and inflammatory reactions. This new work is leading us to the development of an entirely new generation of therapeutics treating autoimmunity and inflammation.
RELapses PrevENTion In Chronic Autoimmune Disease: Common Mechanisms And Co-morbidities (RELENT)
Funder
National Health and Medical Research Council
Funding Amount
$499,837.00
Summary
Treatment of people with chronic autoimmune and inflammatory diseases is not optimal, as we do not know how intensively to treat people, and current treatments often have significant side effects. The RELENT program aims, using multiple approaches, to gain a deeper and more useful knowledge of why these diseases are occuring, what might indicate that disease requires more treatment, and which treatments will be most targeted and have the fewest side effects.
Some infections can start inflammation that, while controlling the infection, can also attack the body tissues of genetically susceptible people. This inflammation can initiate long term problems including arthritis, diabetes and cancer. Our research program seeks to understand who is genetically at risk of this sort of problem and why, and thus to develop new means to prevent and treat the chronic diseases that are initiated in this way.
Unraveling The Link Between HLA B27 And Autoimmunity
Funder
National Health and Medical Research Council
Funding Amount
$746,102.00
Summary
Ankylosing spondylitis and related diseases cause significant morbidity in up to 0.25% of the population. Current treatments have limited efficacy and often debilitating side effects. More targeted peptide antigen based therapies will have fewer side effects and would be of major clinical importance to this group of diseases. This project seeks to identify peptide antigens that could be used in targeted immunotherapy. We also seek to understand how some of the idiosyncratic properties of HLA B27